THANK YOU!

Thank you to all of our supporters who came together at the Hyatt Regency Greenwich April 19th to celebrate the 10th anniversary of Alliance for Cancer Gene Therapy and to honor co-founder Edward Netter.

More than 450 guests at New Frontiers in Cancer Cell & Gene Therapy  mingled with two dozen ACGT scientists who work on the frontlines of cancer research. The event raised $1.4 million; all the money will fund future medical investigators.

Prior to the event, ACGT Scientific Advisory Council members and ACGT Research Fellows held a symposium where they discussed ACGT's cutting-edge research and how ACGT can help bring new therapies to patients. Read more...

BARBARA NETTER IS "DONOR OF THE DAY"

Co-founder Barbara Netter was recently profiled in the column "Donor of the Day" in the NY Metro section of the Wall Street Journal discussing why she and her late husband, Edward, founded ACGT ten years ago. Read the article...

THE 6th ANNUAL SWIM ACROSS AMERICA
GREENWICH - STAMFORD SWIM,
WILL BE HELD SATURDAY, JUNE 30, 2012

LEARN FROM DR. CARL JUNE HOW YOUR SUPPORT OF ACGT MADE LIFE-SAVING LEUKEMIA BREAKTHROUGH POSSIBLE

MEET THE SCIENTISTS

Every day, thanks to your generosity, ACGT Grantees are making enormous progress in the treatments of Lymphoma, Leukemia, Multiple Myeloma, Neuroblastoma, Breast cancer, Ovarian cancer, Lung cancer, Brain cancer, Pancreatic cancer, and Prostate cancer. View a list of our Grantees.

READ THREE EXAMPLES OF OUR SCIENTISTS AT WORK

• Dr. Lotze: Blending Science–Mystery–Hope

• Dr. O'Shea: From Ice Axe to Laboratory

• Dr. Robert Vonderheide, an ACGT Fellow

PATIENT STORIES

At an ACGT-sponsored educational forum on lung cancer, patient Connie Burnett-West discussed her experience with a life-saving gene therapy drug. “Because of gene therapy I am standing here talking to you tonight,” said Burnett-West. Read more....

IN HIS OWN WORDS: ANOTHER PATIENT LIVES BECAUSE OF GENE THERAPY

Five years after gene therapy for Stage IV lung cancer, one trial participant sings the praises of his treatment. “While on the vaccine, I, along with every other patient enrolled in the trial, experienced no negative side effects whatsoever. Chemotherapies may have hit the proverbial ceiling, but the ability of the human body to heal itself, with a little help, has only begun to be tapped.” Early funding for the research that made this treatment possible was awarded by ACGT to Dr. Eckhard Podack at the University of Miami. Read more from this cancer survivor...

ACGT is leading the way in bringing molecular medicine directly to patients with more than 17 clinical trials underway. Now, more than ever, we need your support to continue to fund this breakthrough cancer research. Please donate now.